Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of BLI-489 Administered Intravenously to Healthy Japanese Male Subjects
Latest Information Update: 04 Oct 2018
At a glance
- Drugs BLI 489 (Primary)
- Indications Bacterial infections
- Focus Adverse reactions
- Sponsors Wyeth
- 09 Oct 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 Apr 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 03 Mar 2009 New trial record